18F-FDG PET/CT代谢活跃肿瘤体积联合循环游离DNA显著改善化疗难治性转移性结直肠癌的预后预测
本研究基于前瞻性多中心试验中141例化疗难治性转移性结直肠癌(mCRC)患者(132例可评估OS/PFS),评估基线全身代谢活跃肿瘤体积(WB-MATV)与循环游离DNA(cfDNA)的相关性及联合预后价值。结果显示两者强相关(r=0.70;P<0.001),联合可提高整体预后价值,并识别出低cfDNA高WB-MATV的中间生存亚组。
要点
- 基线WB-MATV与cfDNA强相关(r=0.70;P<0.001),但17%(23/132)患者存在不一致。
- 多因素分析中,高cfDNA是PFS和OS的独立负向预测因子,高WB-MATV是OS的独立负向预测因子。
- 联合WB-MATV与cfDNA可提高预后价值,识别低cfDNA高WB-MATV的中间生存亚组(中位OS 8.1 vs 12.7个月;HR 2.04;P=0.02)。
核心结论
- 联合循环cfDNA与PET-based WB-MATV可提高化疗难治性mCRC患者的预后价值,为风险分层提供依据。
研究设计与样本
- 前瞻性多中心试验纳入141例化疗难治性mCRC患者,其中132例可评估OS/PFS。
- cfDNA从3 mL血浆中提取并用荧光计定量;在18F-FDG PET/CT上勾画所有靶病灶并求和获得WB-MATV。
主要发现
- 基线WB-MATV与cfDNA强相关(r=0.70;P<0.001),但23/132(17%)患者两者不一致。
- 多因素分析识别PFS的3个独立负向预测因子:高cfDNA、短确诊时间、BMI<30。
- 多因素分析识别OS的5个独立负向预测因子:高cfDNA、高WB-MATV、BMI<30、体力状态差、短确诊时间。
- 低cfDNA/高MATV患者中位OS为8.1个月,低cfDNA/低MATV患者为12.7个月(HR 2.04;P=0.02)。
关键数值与推荐
- WB-MATV与cfDNA相关性:r=0.70;P<0.001。
- 低cfDNA/高MATV vs 低cfDNA/低MATV的中位OS:8.1 vs 12.7个月;HR 2.04;P=0.02。
临床怎么用
- 在化疗难治性mCRC患者中,可联合基线cfDNA与PET-based WB-MATV进行风险分层。
- 低cfDNA但高WB-MATV的患者生存结局居中,需关注并可能加强随访或治疗调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Baseline whole-body metabolically active tumor volume (WB-MATV) measured by 18F-FDG PET/CT and circulating cell-free DNA (cfDNA) have been separately validated as predictors of overall and progression-free survival (OS/PFS) in chemorefractory metastatic colorectal cancer (mCRC) patients. This study assessed the correlation between WB-MATV and cfDNA, evaluating the added prognostic value of these in combination, along with clinical parameters. Methods: Of 141 mCRC patients included in a prospective multicenter trial, 132 were evaluable for OS/PFS. cfDNA was extracted from 3 mL of plasma and quantified using a fluorometer. All target lesions were delineated on 18F-FDG PET/CT, and their metabolic volumes were summed to obtain the WB-MATV. Results: Baseline WB-MATV and cfDNA were strongly correlated (r = 0.70; P < 0.001) but showed discordance in 23 of 132 (17%) patients. A multivariate analysis identified 3 independent negative predictors of PFS (high cfDNA, short time since diagnosis, and body mass index < 30) and 5 of OS (high cfDNA, high WB-MATV, body mass index < 30, poor performance status, and short time since diagnosis). Combining WB-MATV and cfDNA increased the overall prognostic value and allowed identification of a subgroup of patients with low cfDNA and high WB-MATV who were associated with intermediate survival (median OS of 8.1 for low-cfDNA/high-MATV patients vs. 12.7 mo for low-cfDNA/low-MATV patients; hazard ratio, 2.04; P = 0.02). Conclusion: This study confirms the added prognostic value of combined circulating cfDNA and PET-based WB-MATV in chemorefractory mCRC patients. The combination of these two biomarkers should provide a firm basis for risk stratification, both in clinical practice and in research trials.
引用
- Woff E, Kehagias P, Vandeputte C, et al. Combining 18F-FDG PET/CT-Based Metabolically Active Tumor Volume and Circulating Cell-Free DNA Significantly Improves Outcome Prediction in Chemorefractory Metastatic Colorectal Cancer. J Nucl Med. 2019. PMID: 30850494. doi:10.2967/jnumed.118.222919
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。